GB2330533A - Composition for enhanced uptake of polar drugs from mucosal surfaces - Google Patents
Composition for enhanced uptake of polar drugs from mucosal surfacesInfo
- Publication number
- GB2330533A GB2330533A GB9900050A GB9900050A GB2330533A GB 2330533 A GB2330533 A GB 2330533A GB 9900050 A GB9900050 A GB 9900050A GB 9900050 A GB9900050 A GB 9900050A GB 2330533 A GB2330533 A GB 2330533A
- Authority
- GB
- United Kingdom
- Prior art keywords
- composition
- mucosal surfaces
- enhanced uptake
- polar drugs
- metabolisable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Botany (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
A composition for administration to a mucosal surface of a mammal comprising a non-metabolisable bile salt analogue and a therapeutic agent. Preferably the non-metabolisable bile salt analogue is a non-naturally occurring conjugate of cholic acid and an amino acid, and in particular cholylsarcosine. Preferably the therapeutic agent is a polar molecule.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9614235.1A GB9614235D0 (en) | 1996-07-06 | 1996-07-06 | Composition for enhanced uptake of polar drugs from mucosal surfaces |
PCT/GB1997/001852 WO1998001159A2 (en) | 1996-07-06 | 1997-07-07 | Composition for enhanced uptake of polar drugs from mucosal surfaces |
Publications (3)
Publication Number | Publication Date |
---|---|
GB9900050D0 GB9900050D0 (en) | 1999-02-24 |
GB2330533A true GB2330533A (en) | 1999-04-28 |
GB2330533B GB2330533B (en) | 2000-10-25 |
Family
ID=10796483
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB9614235.1A Pending GB9614235D0 (en) | 1996-07-06 | 1996-07-06 | Composition for enhanced uptake of polar drugs from mucosal surfaces |
GB9900050A Expired - Fee Related GB2330533B (en) | 1996-07-06 | 1997-07-07 | Composition for enhanced uptake of polar drugs from mucosal surfaces |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB9614235.1A Pending GB9614235D0 (en) | 1996-07-06 | 1996-07-06 | Composition for enhanced uptake of polar drugs from mucosal surfaces |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0993305A2 (en) |
JP (1) | JP2000515503A (en) |
KR (1) | KR20000023583A (en) |
AU (1) | AU722724B2 (en) |
CA (1) | CA2257563A1 (en) |
GB (2) | GB9614235D0 (en) |
NO (1) | NO985956L (en) |
WO (1) | WO1998001159A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6572874B1 (en) * | 1998-05-15 | 2003-06-03 | Umd, Inc. | Vaginal delivery of bisphosphonates |
AU2681300A (en) * | 1999-02-22 | 2000-09-14 | Elan Corporation, Plc | Solid oral dosage form containing an enhancer |
US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
GB2355009A (en) | 1999-07-30 | 2001-04-11 | Univ Glasgow | Peptides conjugated to bile acids/salts |
US7053076B2 (en) | 2001-08-29 | 2006-05-30 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
KR100564021B1 (en) * | 2002-12-11 | 2006-03-24 | 주식회사종근당 | Oral formulations for poorly absorptive hydrophilic drugs |
DE102004027924A1 (en) * | 2004-06-09 | 2005-12-29 | Röhm GmbH & Co. KG | Pharmaceutical form containing the active ingredient cholylsarcosine |
EP2007397B1 (en) | 2006-04-07 | 2013-07-24 | Merrion Research III Limited | Solid oral dosage form containing an enhancer |
TW200950799A (en) | 2008-05-07 | 2009-12-16 | Merrion Res Iii Ltd | Compositions of GnRH related compounds and processes of preparation |
PT3679941T (en) | 2009-06-18 | 2022-11-10 | Serenity Pharmaceuticals Llc | Safe desmopressin administration |
WO2011120033A1 (en) | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
CA2819234A1 (en) | 2011-01-07 | 2012-07-12 | Merrion Research Iii Limited | Pharmaceutical compositions of iron for oral administration |
WO2016120378A1 (en) | 2015-01-29 | 2016-08-04 | Novo Nordisk A/S | Tablets comprising glp-1 agonist and enteric coating |
CN108201531A (en) * | 2016-12-19 | 2018-06-26 | 湖南尔康湘药制药有限公司 | Segmented intestine targeted starch capsule of highly dissoluble sulbenicillin sodium and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990007923A1 (en) * | 1989-01-19 | 1990-07-26 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
DE4222647A1 (en) * | 1991-07-15 | 1993-01-21 | Sandoz Ag | PEPTIDE PREPARATIONS |
WO1995001183A1 (en) * | 1993-06-29 | 1995-01-12 | Ferring B.V. | Compositions for nasal administration of desmopressin |
WO1997006813A1 (en) * | 1995-08-15 | 1997-02-27 | Asahi Kasei Kogyo Kabushiki Kaisha | Mucosal preparation containing physiologically active peptide |
-
1996
- 1996-07-06 GB GBGB9614235.1A patent/GB9614235D0/en active Pending
-
1997
- 1997-07-07 AU AU34539/97A patent/AU722724B2/en not_active Ceased
- 1997-07-07 WO PCT/GB1997/001852 patent/WO1998001159A2/en not_active Application Discontinuation
- 1997-07-07 EP EP97930663A patent/EP0993305A2/en not_active Withdrawn
- 1997-07-07 GB GB9900050A patent/GB2330533B/en not_active Expired - Fee Related
- 1997-07-07 CA CA002257563A patent/CA2257563A1/en not_active Abandoned
- 1997-07-07 JP JP10504949A patent/JP2000515503A/en active Pending
-
1998
- 1998-12-18 NO NO985956A patent/NO985956L/en not_active Application Discontinuation
-
1999
- 1999-01-06 KR KR1019997000028A patent/KR20000023583A/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990007923A1 (en) * | 1989-01-19 | 1990-07-26 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
DE4222647A1 (en) * | 1991-07-15 | 1993-01-21 | Sandoz Ag | PEPTIDE PREPARATIONS |
WO1995001183A1 (en) * | 1993-06-29 | 1995-01-12 | Ferring B.V. | Compositions for nasal administration of desmopressin |
WO1997006813A1 (en) * | 1995-08-15 | 1997-02-27 | Asahi Kasei Kogyo Kabushiki Kaisha | Mucosal preparation containing physiologically active peptide |
Non-Patent Citations (11)
Title |
---|
Chemical Abstract à 112:42406 & Congr. Int. Technol. Pharm.,1989, 1, 91-98 (NAGAI et al.), * |
Chemical Abstract à 95:109081 & Life Sci., 1981, 29(8), 803-809, (ZIV et al.) * |
Chemical Abstract à 98:191258 & Biochem. Pharmacol., 1983, 32(5), 773-776 (ZIV et al.) * |
Int. J. Pharm., 1991, 74(2-3), 95-103, (UCHIDA et al.) "Influence of Bile....Derivatives". * |
J. Controlled Release, 1997, 46(1/02), 17-30 (KRAMER et al.)"Modified Bile.....Peptides and Drugs". * |
J. Pharm. Sci., 1987, 76(5), 351-355, (LONGENECKER et al.) "Effects of ....Insulin in Sheep". * |
J. Pharm. Sci., 1994, 83(10), 1465-1469, (SCOTT-MONCRIEFF etal.) "Enhancement...Micelles in Dogs". * |
J. Pharmacobio-Dyn., 1988, 11(6), 395-401, (NAKADA et al.) "The Effect of Additives....in Rats". * |
J. Pharmacobio-Dyn., 1989, 12(12), 736-743, (NAKADA et al.) "The Effect of Bile..Calcitonin in Rats" * |
J. Pharmacol. Exp. Ther., 1988, 244(1), 23-28,(AUNGST et al)"Comparison...Absorption Promoter". * |
Proc. Natl. Acad. Sci. USA, 1985, 82(21), 7419-7423 (GORDON et al.), "Nasal....Bile Salts". * |
Also Published As
Publication number | Publication date |
---|---|
WO1998001159A3 (en) | 1998-03-26 |
CA2257563A1 (en) | 1998-01-15 |
WO1998001159A2 (en) | 1998-01-15 |
NO985956D0 (en) | 1998-12-18 |
JP2000515503A (en) | 2000-11-21 |
KR20000023583A (en) | 2000-04-25 |
AU722724B2 (en) | 2000-08-10 |
GB9614235D0 (en) | 1996-09-04 |
EP0993305A2 (en) | 2000-04-19 |
NO985956L (en) | 1998-12-18 |
AU3453997A (en) | 1998-02-02 |
GB2330533B (en) | 2000-10-25 |
GB9900050D0 (en) | 1999-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2330533A (en) | Composition for enhanced uptake of polar drugs from mucosal surfaces | |
EP0783299A4 (en) | Compounds and compositions for delivering active agents | |
EP2016950A8 (en) | Pharmaceutical composition comprising an exendin-4 peptide | |
NO20001567D0 (en) | Bioadhesive compositions and methods for topical administration of active agents | |
WO1997044063A3 (en) | Dha-pharmaceutical agent conjugates | |
WO2003079972A3 (en) | Active agent delivery systems and methods for protecting and administering active agents | |
IL143661A0 (en) | Compositions and methods for amelioration of human female sexual dysfunction | |
AU6278298A (en) | Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents | |
UA65561A (en) | Therapeutic agent for lymphatic tumors | |
CA2140361A1 (en) | Composition and methods for decreasing muscle breakdown | |
BR0008443A (en) | Inhibitors of branched-chain amino acid-dependent aminotranspheres and their use in the treatment of diabetic retinopathy | |
WO2002058589A3 (en) | Agents and methods for promoting bone growth | |
AU2001248307A1 (en) | Method for treating kidney disorders | |
RU99103692A (en) | AMINO ACID COMPOSITIONS AND THEIR APPLICATION IN IMMUNO DEPRESSION | |
NO964561D0 (en) | Tri, tetra, penta, and polypeptides, and their use as an antidepressant | |
DK0773782T3 (en) | Terpene derivatives (sarcodictyins) use as antitumor agents | |
AU2921999A (en) | Indole-2,3-dione-3-oxime derivatives for therapeutic use | |
HUP0203050A2 (en) | Treating endometriosis or infertility, or improving fertility | |
WO1999038506A3 (en) | Use of topical preparations of glyceryl trinitrate and lanolin for the treatment of erectile dysfunction | |
AU3739500A (en) | Protease resistant flint analogs | |
AU3354997A (en) | Topical composition containing amino acid in combination with either interferon or thymidine derivatives for treating viral or inflammation diseases | |
DE69815277D1 (en) | NIMELULIDE CONTAINING PHARMACEUTICAL PREPARATION FOR ORAL ADMINISTRATION | |
WO2001045714A3 (en) | Formulations of adenosine a1 agonists | |
CA2386627A1 (en) | Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders | |
UA33773C2 (en) | "reumocain" remedy for preventing and treating pathology of neuromuscular and locomotor systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 20020707 |